Vorträge/Posterpräsentationen
Folgende Vorträge wurden gehalten bzw. Poster präsentiert:
2025
192. Steichert M, Cawello W, Süßenbach FK, Läer S. Angiotensin II/angiotensin I ratio as pharmacodynamic parameter in healthy adults and children with heart failure treated with enalapril: insights from an adult population pharmacokinetic-pharmacodynamic model and the LENA studies. ESDPPP Congress; 2025; Nijmegen, the Netherlands; poster presentation.
https://link.springer.com/article/10.1007/s40272-025-00705-6
191. Schlottau S, Cawello W, Läer S. Model-based blood pressure prediction for personalized medicine for people at any age. ESDPPP Congress; 2025; Nijmegen, the Netherlands; poster presentation.
https://link.springer.com/article/10.1007/s40272-025-00705-6
190. Kinny F, Läer S, Obarcanin E. Continuous glucose monitoring as reference for personalized monitoring for diabetic and healthy people of any age. ESDPPP Congress; 2025; Nijmegen, the Netherlands; oral presentation.
https://link.springer.com/article/10.1007/s40272-025-00705-6
2024
189. Dabidian A. Forschung (er)leben - Neuigkeiten für Ihre pDL Praxis. Expopharm; 2024; München; Vortrag.
188. Steichert M, Läer S, Cawello W. Safe Initial Dosing of Innovative Enalapril Orodispersible Minitablets in Newly Treated Newborns, Infants and Young Children with Heart Failure – Results of a Population Pharmacokinetic Analysis of the LENA Trials. American Heart Association Scientific Sessions; 2024; Chicago, USA.
https://doi.org/10.1161/circ.150.suppl_1.4141312
2023
187. Obarcanin E, Hasanbegovic S, Rustempasic E, Ali Sherazi B, Kinny F, Läer S. Creation of a digital network of Diabetes Type 1 children and adolescents in rural and remote areas in Bosnia and Herzegovina. ESDPPP Congress; 2023; Prague, Czech Republic; poster presentation.
186. Obarcanin E, Ali Sherazi B, Hasanbegovic S, Rustempasic E, Tabakovic S, Kinny F, Läer S. mHealth usability, effectiveness, and satisfaction survey among children, adolescents and care providers in rural and remote municipalities of Bosnia-Herzegovina. ISPAD Conference; 2023; Rotterdam, the Netherlands; poster presentation.
185. Faisal M, Steichert M, Cawello W, Läer S and the LENA consortium. Enalapril orodispersible minitablets for pediatric heart failure - a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials. PAGE meeting; 2023; A Coruña, Spain; abstract 10341:31.
https://www.page-meeting.org/?abstract=10341
2022
184. Sayyed S, Sharkas AR, Ali Sherazi B, Dabidian A, Schwender H, Läer S. Innovative high-fidelity simulation for vaccination training of pharmacists including emergency cases - a randomized controlled study. ESDPPP Congress; 2022; Liverpool, Great Britain; oral presentation.
183. Dabidian A, Ali Sherazi B, Schlottau S, Obarcanin E, Läer S. mHealth Diabetes Apps for the delivery of Pharmaceutical Care and Inter-professional point of care communication in Adolescent Type 1 Diabetes Mellitus patients. ESDPPP Congress; 2022; Liverpool, Great Britain; poster presentation.
182. Steichert M, Cawello W, Breur JMPJ, Male C, de Wildt SN, Läer S. Plasma renin activity in young children with heart failure: influence of age, disease and ACE inhibitor treatment. ESDPPP Congress; 2022; Liverpool, Great Britain; oral presentation.
2019
181. Deters MA, Obarcanin E, Schwender H, Läer S. Proof of Concept Studie EMDIA – effektives Medikationsmanagement für Patienten mit Diabetes mellitus Typ 2. Jahrestagung der DGKPha; 2019; Aachen; Posterpräsentation und Vortrag.
180. Ali M, Tins J, Burckhardt BB. Establishing the integrity of the continuous paediatric pharmacokinetic bioanalysis for clinical trial within an academia environment using quality assessment process. ESDPPP Congress; 2019; Basel, Switzerland.
https://adc.bmj.com/content/104/6/e19.2
179. Ali M, Läer S, Burckhardt BB. LC-MS/MS method for screening of intoxication and drug adherence of angiotensin converting enzyme inhibitors in plasma. MSACL; 2019; Salzburg, Austria.
178. Feickert M, Burckhardt BB. Design of experiments as a key element for enabling the endogenous mass spectrometric determination of Substance P and related Hemokinin-1. Euroanalysis; 2019; Istanbul, Turkey; oral presentation OP-009:136.
177. Feickert M, Burckhardt BB. A quality-controlled and design of experiments-based approach for the optimization of the chromatographic solvent composition for the determination of Substance P and Hemokinin-1. HPLC; 2019; Milan, Italy:376.
176. Feickert M, Burdman I, Makowski N, Ali M, Farahani S, Majid H, Ciplea AM, Bartel A, Burckhardt BB. Reliable results in continuous bioanalysis of paediatric renin samples – comprehensive quality assessment within clinical studies in children. ESDPPP Congress; 2019; Basel, Switzerland:34.
https://doi.org/10.1136/archdischild-2019-esdppp.72
175. Feickert M, Burckhardt BB. Aprepitant in the prevention of cardiotoxic adverse effects of Doxorubicin in the paediatric population - a systematic literature investigation. ESDPPP Congress; 2019; Basel, Switzerland:35.
https://doi.org/10.1136/archdischild-2019-esdppp.73
174. Farahani I, Laven A, Farahani S, Deters MA, Feickert M, Süßenbach FK, Schwender H, Läer S. Effectiveness of OSCEs in training German pharmacy students in consultation on self-medication - a randomised controlled investigation. ESDPPP Congress; 2019; Basel, Switzerland:33.
173. Gangnus T, Süßenbach FK, Makowski N, Burdman I, Läer S, Burckhardt BB. Reference ranges of blood NT-proBNP in paediatric heart failure and healthy controls: compilation of literature data. ESDPPP Congress; 2019; Basel, Switzerland; Poster presentation poster P37; Archives of Disease in Childhood, 104(6):e32.
https://adc.bmj.com/content/104/6/e32.2
172. Gangnus T, Burckhardt BB. Mobile phase optimization applying a design of experiments approach to increase the signal response in LC-MS/MS of bradykinin and its internal standard. HPLC; 2019; Milan, Italy; Poster presentation: poster 291.
171. Gangnus T, Burckhardt BB. A lean approach to examine surface absorption of the low-abundant peptide bradykinin and to increase its signal intensity in LC-MS/MS: a design of experiments concept. Euroanalysis; 2019; Istanbul, Turkey; Poster presentation: poster PP2-041; Poster 041:3. Platz beim Springer Poster Pitch Presentations Award.
170. Farahani S, Feles E, Burckhardt BB, Läer S on behalf of the LENA consortium. Depiction of haematological and biochemical laboratory normal reference values in a European multicentre paediatric trial. ESDPPP Congress; 2019; Basel, Switzerland: P32.
169. Deters MA, Obarcanin E, Schwender H, Läer S. Assessment of selected pharmaceutical care components for coaching community pharmacists in medication therapy management (MTM) for patients with diabetes. ESCP Congress; 2019; Ljubljana, Slovenia; poster CP-PC021.
168. Deters MA, Laven A, Castejon AM, Doucette WR, Ev LS, Krass I, Mehuys E, Obarcanin E, Schwender H, Läer S. A meta-analysis of pharmaceutical care components for diabetes patients. DDG Kongress; 2019; Berlin: poster EP30.
167. Faisal M, Cawello W, Läer S. Simultaneous population pharmacokinetic analysis of enalapril in serum and urine administered using orodispersible mini-tablets for use in children. ASCPT; 2019; Washington, USA; Poster Session (PIII-042); Clinical Pharmacology & Therapeutics. 2019; 105(S1):S94.
https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1344
2018
166. Makowski N, Süßenbach FK, Burckhardt BB. A novel GCLP-compliant bioanalytical LC-HRMS method for the reliable determination of aldosterone, precursor and metabolite facilitating further insight into paediatric maturation of the renin-angiotensin-aldosterone-system. DPhG Jahrestagung; 2018; Hamburg; Tagungsband POS. 100:134.
165. Burdman I, Burckhardt BB. Appraisal of immunocapture by different antibodies prior to a surrogate peptide approach utilizing LC-HRMS analysis for quantification of the low abundant protein renin in human plasma. DPhG Jahrestagung; 2018; Hamburg; Tagungsband POS. 100:134.
164. Majid H, Kottke D, Bartel A, Burckhardt BB. Approach of a physiologically-based permeation model utilizing LC-MS/MS to investigate the Safety Potential of Buccal Drug Applications. DPhG Jahrestagung; 2018; Hamburg; Tagungsband POS. 162:164 -5.
163. Süßenbach FK, Makowski N, Burckhardt BB. Evaluation of RAAS peptides in complex biological matrices in paediatric patients: Development and validation of a low-volume LC-HRMS Method. DPhG Jahrestagung; 2018; Hamburg, Tagungsband POS. 121:144 sowie Poster session (PI 121); Tagungsband POS. 121:144.
162. Kottke D, Majid H, Breitkreutz J, Burckhardt BB. Ex vivo permeation studies to facilitate the development of a buccal child-appropriate dosage form by using lidocaine. BioBarriers; 2018; Saarbrücken; POS. 165:113.
161. Faisal M, Cawello W, Läer S. Pharmacokinetic comparison of enalapril administered using market authorized and child appropriate dosage formulations. ACCP; 2018; Seattle, USA. Pharmacometrics in NRW; Köln, Poster Sessions. JACCP; 2018; 1(2):265; poster 382.
https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/jac5.1059
160. Burckhardt BB, Ciplea AM, Laven A, Kleine K, Ablonczy L, Breur JMPJ, Dalinghaus M, van der Meulen M, Klingmann I, Spatenkova L, Swoboda V, Bajcetic M, Keatley-Clark A, Läer S, Lagler FB. Tailored simulation training as an innovative Training concept to facilitate successful study conduct and recruitment encompassing its assessment. ASCPT; 2018; Orlando, USA; congress contribution.
2017
159. Burckhardt BB, Laven A, Kleine K, Ablonczy L, Breur JMPJ, Dalinghaus M, van der Meulen M, Klingmann I, Spatenkova L, Swoboda V, Bajcetic M, Keatley-Clark A, Läer S, Lagler FB. Innovative training concept to overcome main reasons for failed pediatric clinical trials and to facilitate successful study conduct and recruitment. Annual conference of the American Heart Association; 2017.
158. Deters MA, Laven A, Castejon AM, Doucette WR, Ev LS, Krass I, Mehuys E, Obarcanin E, Schwender H, Läer S. Effective interventions for diabetes patients by community pharmacists – a meta-analysis of pharmaceutical care components. ESCP; 2017; Heidelberg, abstracts:68, poster CP-PC024.
157. Laven A, Deters MA, Rose O, Schwender H, Smaranda A, Waltering I, Läer S. PHARMADHERE Study - How to train community pharmacists to provide efficient pharmaceutical care interventions to foster adherence. ESCP; 2017; Heidelberg.
156. Makowski N, Castro Diez C, Dalinghaus M, DeWildt S, Van der Meulen M, Bajcetic M, Jovanovic I, Male C, Ablonczy L, Szatmári A, Schwender H, Läer S. Standard of care for children with heart failure in Europe: Results of a survey and a subsequent Delphi questionnaire. ESDPPP Congress; 2017; Leuven, Belgium.
155. Burckhardt BB, Ciplea AM, Kleine K, Ablonczy L, Breur JMPJ, Dalinghaus M, van der Meulen M, Klingmann I, Spatenkova L, Swoboda V, NN Serbien, Keatley-Clark A, Läer S, Lagler F. Novel tailored training concept to facilitate successful study conduct and optimize recruitment in paediatric clinical trials. ESDPPP Congress; 2017; Leuven, Belgium.
154. Deters MA, Läer S, Obarcanin E. Transition instead of transfer for drug treatment in adolescent diabetes type 1. ESDPPP Congress; 2017; Leuven, Belgium; Abstracts:22, poster PP-8.
2016
153. Burckhardt BB, Ciplea AM, Laven A, Klingmann I, Läer S, Lagler F. A novel simulation-based approach to train study teams for clinical trials in neonates, infants and children with heart failure. Annual Meeting of the Association for European Paediatric and Congenital Cardiology; 2016; Rome, Italy.
152. Deters MA, Obarcanin E, Läer S. Pharmaceutical care provided by community pharmacists for adolescents with type 1 diabetes mellitus - follow-up of DIADEMA. DPhG Jahrestagung; 2016; München, Tagungsband POS. 81:118.
151. Rasool MF, Khalil F, Läer S. Optimizing clinical use of carvedilol in liver cirrhosis - a physiologically based pharmacokinetic approach. Pharmacometrics in NRW; 2016; Bonn.
2015
150. Rasool MF, Khalil F, Läer S. A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients. Annual Simcyp Virtual Seminar on Applications of Population-based IVIVE and PBPK; 2015.
149. Khalil F, Läer S. Bedeutung des “Off Label Gebrauchs” in der Pädiatrie: Ist off Label auch Off Knowledge? vfa/Kindernetzwerk-Veranstaltung “Licht am Horizon”; 2015; Frankfurt.
148. Khalil F. Physiologically based pharmacokinetic modelling in children. IATDMCT; 2015; Rotterdam, the Netherlands.
147. Schäfer C, Cawello W, Andreas JO. High predictability of plasma lacosamide and no differences by different age and gender through normalization processes. DPhG Annual Meeting; 2015; Düsseldorf.
146. Rasool MF, Khalil F, Läer S. Investigation of altered organ blood flow on carvedilol disposition in adult and pediatric chronic heart failure patients by using PBPK modelling. DPhG Annual Meeting; 2015; Düsseldorf.
145. Ciplea AM, Kleine K, Burckhardt BB, Läer S, Breitkreutz J, Špatenková L, Klingmann I. Implementation of a GxP compliant quality system encompassing all consortium members of the FP-7 funded LENA Project. DPhG Annual Meeting; 2015; Düsseldorf.
144. Schäfer J, Burckhardt BB, Tins J, Läer S. Child-appropriate high throughput HPLC-MS/MS for enalapril and enalaprilat in small sample volumes of serum and urine within a GCLP-compliant environment. DPhG Annual Meeting; 2015; Düsseldorf.
143. Makowski N, Castro Diéz C, Khalil F, Läer S. Reliability and validity of an European survey on the pharmacological management of paediatric heart failure. DPhG Annual Meeting; 2015; Düsseldorf.
142. Burckhardt BB, Tins J, Läer S. Evaluation of a regulatory-compliant bioanalytical setting suitable to determine pharmacokinetics and pharmacodynamics of enalapril in Phase II/III studies in all paediatric age groups. DPhG Annual Meeting; 2015; Düsseldorf.
141. Rasool MF, Khalil F, Läer S. Physiologically based pharmacokinetic models for adult and paediatric chronic heart failure patients using the example of carvedilol treated patients. ESDPPP Congress; 2015; Belgrade, Serbia.
140. Obarcanin E, Läer S. Pharmaceutical care of adolescents with T1DM, DIADEMA Study; ESDPPP Congress; 2015; Belgrade, Serbia.
139. Ciplea AM, Kleine K, Burckhardt BB, Läer S, Breitkreutz J, Špatenková L, Klingmann I. Development and establishment of a quality-framework for the LENA project. ESDPPP Congress; 2015; Belgrade, Serbia.
138. Schäfer J, Burckhardt BB, Tins J, Läer S. Child-appropriate high throughput HPLC-MS/MS for enalapril and enalaprilat in small sample volumes of serum and urine within a GCLP-compliant environment. ESDPPP Congress; 2015; Belgrade, Serbia.
137. Castro Díez C, Khalil F, Dalinghaus M, van der Meulen M, de Wildt S, Jovanovic I, Bajcetic M, Burch M, Male C, Klingmann I, Szatmári A, Ablonczy L, Schwender H, Läer S.. Design of a European survey on the pharmacological management of paediatric heart failure. ESDPPP Congress; 2015; Belgrade, Serbia.
136. Burckhardt BB, Tins J, Läer S. Innovative regulatory-conforming bioanalytical approaches enabling systematic investigations of pharmacokinetics and pharmacodynamics by paediatric clinical studies in all age groups. ESDPPP Congress; 2015; Belgrade, Serbia.
135. Rasool MF, Khalil F, Läer S. A PBPK approach for predicting carvedilol exposure in chronic heart failure. Pharmacometrics in NRW; 2015; Münster.
2014
134. Obarcanin E, Krüger M, Läer S. Pharmaceutical care of adolescents with T1DM, DIADEMA study. DDG Annual Symposium; 2014; Berlin.
133. Obarcanin E, Krüger M, Läer S. Medikationsmanagement in Apotheken am Beispiel von Jugendlichen mit Diabetes Typ 1 (DIADEMA); DPhG Vortrag; 2014; Düsseldorf.
132. Schäfer C, Cawello W, Andreas JO. High Predictability of Plasma Lacosamide and No Relevant Differences by Age and Gender Following Normalization. 2014; Seattle, USA; P4.261.
https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P4.261
131. Schäfer C, Cawello W, Andreas JO. Immediate Steady-state Concentration in Plasma after Oral or Intravenous Lacosamide Loading Dose. 2014; Seattle, USA; P4.263.
https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P4.263
130. Laven A, Schäfer J, Läer S. PHARMAGRIPS: Structured pharmaceutical counseling in the self-medication of the common cold. A randomised controlled study (RCT). FIP Annual Meeting; 2014; Bangkok, Thailand.
129. Khalil F., Läer S. Physiologically based pharmacokinetic Models in the prediction of oral Drug exposure over the entire pediatric age range-sotalol as a model drug. Simcyp Virtual Seminar; 2014.
128. Khalil F, Läer S. WP 5: Modeling and Simulation- Top line PK-result of WP07 and implications for WP08-WP10. LENA General Assembly Meeting; 2014; Salzburg, Austria.
127. Khalil F. Application of paediatric PBPK models in drug development and research for ivabradine and amiodarone. Pharmacometrics in NRW; 2014; Düsseldorf.
126. Rasool MF, Khalil F, Läer S. A PBPK model for assessing impact of reduced organ blood flows on carvedilol exposure in heart failure. Pharmacometrics in NRW; 2014; Düsseldorf.
2013
125. Khalil F, Läer S. A bottom-up approach to simulate amiodarone pharmacokinetics in children. Pharmacometrics in NRW; 2013; Cologne.
124. Khalil F, Läer S. Physiologically based pharmacokinetic models to describe oral sotalol exposure from adults to children. A comparison of two modeling software. Pharmacometrics in NRW; 2013; Cologne.
123. Burckhardt BB, Ramusovic S, Tins J, Läer S. Tailored bioanalytical methods for determination of aliskiren, enalapril and enalaprilat in serum and urine for systematic pharmacokinetic investigations in paediatric patients. ESDPPP Congress; 2013; Salzburg, Austria.
122. Laven A, Läer S. Evidenzbasierte Leitlinien für die Selbstmedikation: Anforderungen der Pharmazeuten für den Apothekenalltag. Jahrestagung des Deutschen Netzwerks für Evidenzbasierte Medizin. 2013; Berlin.
121. Ehlers B, Läer S. Computerized physician order entry and clinical decision support systems in pediatrics – a literature overview. ESDPPP Congress; 2013; Salzburg, Austria.
120. Lüpken R, Läer S. Requirements for a physiologically based pharmacokinetic model of tacrolimus in adults. ESDPPP Congress; 2013; Salzburg, Austria.
119. Lüpken R, Läer S. Tacrolimus pharmacokinetics in transplanted patients: Role of pharmacogenetics background of patients; Pharmacometrics Platform; 2013; Cologne.
118. Lüpken R, Läer S. Requirements for a physiologically based pharmacokinetic model of tacrolimus in adults. ESDPPP Congress; 2013; Salzburg, Austria.
117. Rasool F, S. Läer. Physiologically based pharmacokinetic modeling of carvedilol. Pharmacometrics in NRW; 2013; Cologne.
116. Rasool F, S. Läer. Approaches for Physiologically based pharmacokinetic modeling of carvedilol. ESDPPP Congress; 2013; Salzburg, Austria.
2012
115. Khalil F, Läer S. Assembling of a multicenter and multinational data base to develop and validate a physiologically based pharmacokinetic sotalol model for pediatric extrapolation. Annual Meeting in National Harbor; 2012; Maryland, USA.
2011
114. Burckhardt BB, Ramusovic S, Jaffan L, Läer S. Identification of children at risk for high blood pressure out of routine blood pressure monitoring data. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
113. Lüpken R, Läer S. FDA labled biomarkers in the personalized medicine of drug prescriptions on a pediatric ward. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
112. Schunk C, Heiter D, Lüpken R, Läer S. Self-medication in Germany: The new role of pharmacists to contribute to pharmacovigilance. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
111. Khalil F, Läer S. Physiologically-based pharmacokinetic modeling as a tool to explore drug disposition in newborns and infants and point to a new area of research. ESDPPP Congress; 2011; Oslo, Norway.
110. Khalil F, Läer S. Physiology-based pharmacokinetic modeling as a tool to explore drug disposition in pediatrics and point to a new area of research. Clinical Trials in Pediatrics; 2011; Genoa, Italy.
109. Jaffan L, Gorny M, Läer S. High susceptibility for prescribing errors of pro re nata (on demand) medication jeopardize children's medication safety in a hospital setting. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
108. Müller SM, Jaffan L, Kloiber E, Läer S. Dextromethorphan use and abuse in German adolescents: Do we need to change its market access? ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
107. Schunk C, Heiter D, Lüpken R, Läer S. Self-medication in Germany: The new role of pharmacists to contribute to pharmacovigilance. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
106. Lüpken R, Läer S. FDA labled biomarkers in the personalized medicine of drug prescriptions on a pediatric ward. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
105. Burckhardt BB, Ramusovic S, Jaffan L, Läer S. Identification of children at risk for high blood pressure out of routine blood pressure monitoring data. ÖPhG- und DPhG-Jahrestagung; 2011; Innsbruck, Austria.
104. Gorny M, Jaffan L, Läer S. “KinderDosierung”, a Clinical Decision Support System for children: A novel tool to increase medication safety. ESDPPP Congress; 2011; Oslo, Norway.
2010
103. Khalil F, Ramusovic S, Läer S. Paediatric drug trials and clinical practice- challenges for clinical pharmacists. Expert Workshop "Can the "in silico Child" help to develop better medicines for our children"; 2010; Genua, Italy.
102. Jaffan L, Gorny M, Läer S. Medication errors in pediatric inpatients: Identification and prevention by a clinical pharmacist. DPhG-Tagung; 2010; Braunschweig.
101. Läer S. Pediatric Drug Development and Future Directions. American Heart Association, Scientific Sessions; 2010; Chicago, USA; Session 3012; oral presentation.
100. Ramusovic S, Frobel A-K, Läer S. Physiology Based Modeling to Support Pediatric Cardiovascular Drug Research - Potential Applications Using Amiodarone and Enalapril as Examples. American Heart Association, Scientific Sessions; 2010; Chicago, USA; Session 3012; oral presentation: circulation 122, A19468.
99. Frobel AK, Ramusovic S, Läer S. Physiologically - Based Pharmacokinetic (PBPK) Modeling of Bisoprolol in Adults and Children and External Model Validation in a Paediatric Clinical Trial. meeting of the Population Approach Group in Europe; 2010; Berlin; ISSN 1871-6032:19 abstract 1780.
98. Ramusovic S, Willmann S, Läer S. System biology for drug therapy - a mechanistic physiology based model of the interaction between enalapril and the Raa-System. 2010; Atlanta, USA; Clinical Pharmacology and Therapeutics; 87: S9-37.
97. Ramusovic S, Frobel AK, Willmann S, Läer S. An integrated whole-body physiology based pharmacokinetic / pharmacodynamic model of enalapril and the RAA - system. meeting of the Population Approach Group in Europe; 2010; Berlin; ISSN 1871-6023:19 abstract 1865.
96. Gorny M, Jaffan L, Läer S. Dosage Recommendations for Children: "Kinder Dosierung", a Web Based Clinical Decision Support System for Children. Deutscher Kongress für Patientensicherheit bei medikamentöser Therapie; 2010; Berlin.
95. Jaffan L, Gorny M, Läer S. Identification and prevention of mediication errors by a clinical pharmacist on a paediatric ward. Deutscher Kongress für Patientensicherheit bei medikamentöser Therapie; 2010; Berlin.
2009
94. Ramusovic S, Willmann S, Läer S. A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System. PAGE meeting; 2009; Saint Petersburg, Russia.
93. Vogt W, Läer S. European survey on the pharmacological management of low cardiac output syndrome in children undergoing cardiac surgery with cardiopulmonary bypass (EuLoCOS-Paed). ESDPPP Congress; 2009; Chamonix, France.
92. Ramusovic S, Läer S. A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System. ESDPPP Congress; 2009; Chamonix, France.
91. Khalil F, Läer S. Development of a physiologically based pharmacokinetic model for a typical “kidney drug” -Sotalol- in adults and children. ESDPPP Congress; 2009; Chamonix, France.
90. Jaffan L, Vogt W, Läer S. Drug-related problems on paediatric wards: Proposing a “PCNE for children” for hospital quality management in paediatric pharmacotherapy. ESDPPP Congress; 2009; Chamonix, France.
89. Gorny M, Läer S. Dosage Recommendations for Children: Developing a Clinical Decision Support System for Pediatrics. ESDPPP Congress; 2009; Chamonix, France.
88. Frobel AK, Läer S. Physiology-based pharmacokinetic simulation of bisoprolol as a rationale for dosing in future paediatric clinical trials. ESDPPP Congress; 2009; Chamonix, France; oral presentation.
87. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. Basic & Clinical Pharmacology & Toxicology. 2009; 104(6):501.
https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2009.00424.x
86. Frobel AK, Läer S. Physiology-based simulations help to find bisoprolol as a rational drug of choice for a randomised controlled trial in children with congestive heart failure. DGK-Jahrestagung; 2009; Mannheim; Vortrag V72.
85. Hsien L, Vogt W, Läer S. Simulation of sildenafil disposition in virtual children by means of a physiologically based pharmacokinetics modelling. Naunyn Schmiedeberg´s Archives of Pharmacology. 2009; 379 Supplement 1.
84. Gorny M, Läer S. A clinical decision support system for paediatrics: progress of development. Naunyn Schmiedeberg´s Archives of Pharmacology. 2009; 379 Supplement 1, 497.
83. Frobel AK, Läer S. Identifying bisoprolol as the beta-blocker of choice for a clinical trial in children with congestive heart failure using physiology-based pharmacokinetic simulation. Naunyn Schmiedeberg´s Archives of Pharmacology. 2009; 379 Supplement 1, 496.
82. Breddemann A, Laws J, Bührmann S, Dohna-Schwake C, Tot E, Läer S. Validation of physiologically-based simulations for cidofovir pharmacokinetics in critically ill paediatric patients. Naunyn Schmiedeberg´s Archives of Pharmacology. 2009; 379 Supplement 1, 495.
81. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. Naunyn Schmiedeberg´s Archives of Pharmacology. 2009; 379 Supplement 1, 473.
2008
80. Vogt W, Frobel AK, Ramusovic S, Läer S. The in silico child helps to design paediatric dosing regimens a priori: an example with Milrinone. Clinical Research in Cardiology. 2008; 97:707.
79. Frobel AK, Schmidt KG, Hulpke-Wette M, Läer S. Evidence for the use of beta-adrenoceptor-blockers in paediatric congestive heart failure: a Cochrane Review. Jahrestagung der DPhG; 2008; Abstractband: Posterbeitrag B69.
78. Breddemann A, Laws J, Bührmann S, Tot E, Läer S. Physiologically-based pharmacokinetic modelling and clinical pharmacokinetics of cidofovir in paediatric patients. Jahrestagung der DPhG; 2008; Abstractband: Vortrag K33.
77. Gorny M, Jaffan L, Läer S. Development of a clinical decision support system for children. Jahrestagung der DPhG; 2008; Abstractband: Posterbeitrag B70.
76. Schmidt D, Läer S. Discrimination of serotonin transporter polymorphism genotypes using real time PCR. Jahreskongress für Klinische Pharmakologie; 2008; Berlin.
75. Nir A, Lindberger A, Rauh M, Bar-Oz B, Läer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS. Normal values, range and upper limits of Nt-pro-B-type natriuretic peptide in infants and children. Analysis and combined from 4 studies. 2008; Cardiology in the Young; 18, Supplement 1, 40.
74. Ramusovic S, Vogt W, Läer S. Simulation of a virtual paediatric population as a basis for an amiodarone dosing regimen. 2008; Cardiology in the Young; 18, Supplement 1, 40.
73. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt K G, Läer S. Off-label drug use among hospitalised children: Identifying areas with the highest need for research. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children; 2008; Rotterdam, the Netherlands:115.
72. Breddemann A, Laws J, Bührmann S, Tot E, Läer S. Combination of physiologically-based pharmacokinetic simulations with detection of paediatric cidofovir pharmacokinetics: Rationale of a multi centre clinical trial. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children; 2008; Rotterdam, the Netherlands:37.
71. Frobel AK, Ramusovic S, Vogt W, Läer S. Simulation of metoprolol plasma concentracion profiles in children using a physiologically based pharmacokinetic model as a basis for paediatric dosing recommendations. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children; 2008; Rotterdam, the Netherlands:73.
70. Vogt W, Ramusovic S, Frobel AK, Läer S. Evaluation of a physiologically based pharmacokinetic model of milrinone for children undergoing cardiac surgery. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children; 2008; Rotterdam, the Netherlands:94.
69. Ramusovic S, Vogt W, Frobel AK, Läer S. Physiologically based modelling for the development of a paediatric dose regimen for oral long-term therapy with amiodarone. In Proceedings of the 11th ESDP Congress Safe and effective medicines for children; 2008; Rotterdam, the Netherlands:90.
2007
68. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt K, Läer S. High rate of off-label use in cardiovascular paediatric pharmacotherapy requires new focus in research. Naunyn Schmiedeberg´s Archives of Pharmacology. 2007; 375 Supplement R 564.
67. Breddemann A, Läer S, Schmidt KG, Harjes M, Adam R, Ludwig A, Niehues T, Schneider DT. Case Report: Severe gastrointestinal inflammation related to persistent HHV-6B infection in a 10-month old cancer patient. Naunyn Schmiedeberg´s Archives of Pharmacology. 2007; 375 Supplement R 563.
66. Röhm S, Frobel AK, Tot E, Läer S. Actual necessity of predictive CYP2D6-gendiagnostics in psychiatric therapy. Naunyn Schmiedeberg´s Archives of Pharmacology. 2007; 375 Supplement R 537.
2006
65. Verde PE, Albers S, Läer S. Statistical analysis and confidence intervals for the maximum oxygen uptake for a subject: a modern statistical approach. ISCB Conference; 2006.
2005
64. Läer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M. Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol using clinical trial simulation and population pharmacokinetics. Zeitschrift für Kardiologie. 2005; 94 Supplement 1.
63. Läer S, Albers S, Gupta M, Mir TS, Meibohm B. Population pharmacokinetics of carvedilol in pediatric patients with congestive heart failure. Clinical Pharmacology and Therapeutics. 2005; 77:88; PII-144:88.
https://doi.org/10.1016/j.clpt.2004.12.229
2004
62. Albers S, Mir TS, Falkenberg J, Haddad M, Budden R, Weil J, Läer S. Valuation of NBNP for Pediatric Patients in Multicenter Studies. Zeitschrift für Kardiologie. 2004; 93;739.
61. Albers S, Mir TS, Falkenberg J. Flato M, Haddad M, Budden R, Weil J, Läer S. Evaluation of the cardiac biomarker Nt-pro BNP in children to guide harmacotherapy. ESDP Meeting; 2004: 114.
60. Läer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Hulpke-Wette M. Development of a Pediatric Dosing Regimen for Sotalol. ESDP Meeting; 2004:72.
59. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, Albers S, Läer S. Plasma concentrations of N-terminal brain natriuretic peptide (n-bnp) in healthy children and adolescents: reference values and effect of age and gender. Zeitschrift für Kardiologie. 2004; 93, supplement 3.
58. Kindermann M, Maack C, Schaller S, Finkler N, Läer S, Wuttke H, Böhm M. Atypisch hohe Affinität von Carvedilol, aber nicht Metoprolol, zu humanen β-Adrenozeptoren bewirkt prolongierte β-adrenerge Inhibition auch nach kompletter Plasma-Elimination. Zeitschrift für Kardiologie. 2004, supplement 3.
2003
57. Kindermann M, Maack C, Schaller S, Finkler N, Läer S, Wuttke H, Böhm M. Atypical binding of carvedilol to betaadrenoceptors prevents betareceptor rebound phenomen. Circulation. 2003; 108, Supplement, IV-465.
56. Läer S, Elshoff JP, Mir TS, Hulpke-Wette M, Weil J. Body weight and age for individually adjusted a priori sotalol dosing in children with supraventricular achycardia. Circulation. 2003; 108, Supplement, IV-370.
55. Läer S, Elshoff JP. Microdialysis as a new blood free method to determine plasma drug levels in pediatric patients. Zeitschrift für Kardiologie. 2003; 92, I/183-184.
54. Läer S, Elshoff JP, Mir TS, Müller-Wolf C, Weil J, Hulpke-Wette M, Meibohm B. Dosing rationale using population pharmacokinetics of sotalol in children with tachycardia. Naunyn Schmiedeberg´s Archives of Pharmacology. 2003; 367 Supplement R 114.
53. Meibohm B, Zhang W, Elshoff JP, Behn F, Hulpke-Wette M, Läer S. Population pharmacokinetics and pharmacodynamics of sotalol in infants and children with tachycardia. Clinical Pharmacology & Therapeutics. 2003; 73, PIII-37, 71.
2002
52. Läer S, Elshoff JP, Zhang W, Meibohm B. Population pharmacokinetic modeling for sotalol in pediatric patients with tachycardia. European Journal of Clinical Pharmacology. 2002; 58, S76.
51. Mir TS, Marohn S, Eiselt M, Haun C, Läer S, Laux R, Weil J. Plasma Concentrations of N-Terminal Brain Natriuretic Peptide (N-BNP) in healthy children and in children with heart diseases. Circulation. 2002.
50. Mir TS, Marohn S, Läer S, Eiselt M, Haun C, Hellwege HH, Laux R, Weil J. Nt-pro-brain natriuretic peptide (N-BNP) zur Diagnostik, Risikostratifizierung und Therapiesteuerung bei Kindern mit angeborenen und erworbenen Herzerkrankungen. Kongreß im Rahmen der 51. Jahrestagung der Norddeutschen Gesellschaft für Kinderheilkunde und Jugendmedizin; 2002; Hamburg.
49. Läer S, Behn F, Meibohm B. Developmental pharmacodynamics of carvedilol in pediatric patients with congestive heart failure. 4th International Symposium: Advances in simultaneous pharmacokinetic/pharmacodynamic modelling; 2002;, Noordwijkerhout, the Netherlands.
48. Kirchhoff P, Degen L, Fabritz L, Läer S, Neumann J, Haverkamp. Post-repolarization refractoriness and flattened restitution - a novel explanation for the antiarrhythmic efficacy of amiodarone. Naunyn Schmiedeberg´s Archives of Pharmacology. 2002; 365 Supplement, R 110.
47. Behn F, Scholz H, Läer S. Different development of the pharmacokinetics of R- and Scarvedilol in children with heart failure. Naunyn Schmiedeberg´s Archives of Pharmacology. 2002; 365 Supplement, R 110.
46. Elshoff JP, Scholz H, Läer S. Microdialysis as a tool for pharmacokinetic studies in special populations - experiments with sotalol. Naunyn Schmiedeberg´s Archives of Pharmacology. 2002; 365 Supplement, R 109.
2001
45. Behn F, Läer S, Scholz H, Mir TS, Weil J, Meibohm B. Enantiospecific PK/PD-modeling of heart rate and mean arterial pressure during carvedilol treatment in children with congestive heart failure. ESDP Congress; 2001; Limassol, Cyprus; Abstract p22.
44. Läer S, Elshoff JP, Scholz H, Wauer I, Meibohm B, Mir TS, Weil J, Hulpke-Wette M. Developmental changes in proarrhythmic and antiarrhythmic action of sotalol in children with tachycardia. Circulation. 2001; 104, Supplement II, II-488/489.
43. Läer S, Behn F, Scholz H, Eiselt M, Mir TS, Weil J, Meibohm B. Successful therapy with carvedilol in pediatric patients with myocardial failure. Circulation. 2001; 104, Supplement II, II- 679.
42. Behn F, Eiselt M, Läer S, Mir TS, Scholz H, Weil J. Effects of the beta-adrenoceptor blocker carvedilol in children with myocardial failure. XXXIV International Congress of Physiological Sciences; 2001; Christchurch, New Zealand; Abstract Nr. 26.
41. Läer S, Behn F, Elshoff JP, Scholz H, Wauer I, Hulpke-Wette M, Meibohm B, Mir TS, Weil J. Drug response in pediatric patients with heart disease. Naunyn Schmiedeberg´s Archives of Pharmacology. 2001; 363 Supplement, R 117.
40. Läer S, Wauer I, Elshoff JP, Meibohm B, Scholz H, Mir TS, Weil J, Hulpke-Wette M. Effects of sotalol in pediatric patients: evidence for developmental changes in sotalol´s proarrhythmic and antiarrhythmic action. Zeitschrift für Kardiologie. 2001; 90, II/55.
39. Läer S, Behn F, Scholz H, Mir TS, Weil J, Meibohm B. Carvedilol for pediatric congestive heart failure: do young children behave like little adults? Clinical Pharmacology & Therapeutics. 2001; 69, PII-79, 52.
2000
38. Elshoff JP, Läer S, Wauer I, Behn F, Scholz H. Microdialysis in venous blood samples adding a colloid to the perfusion fluid - an in vitro study. European Journal of Clinical Pharmacology. 2000; 56, A 24.
37. Wauer I, Läer S, Behn F, Scholz H, Hulpke-Wette M, Mir TS, Weil J, Meibohm B. Sotalol in pediatric patients with supraventricular tachycardia: dosage regimens based on body weight or on body surface area? European Journal of Clinical Pharmacology. 2000; 56, A 18.
36. Mir TS, Mahron S, Eiselt M, Läer S, Scholz H, Weil J. Effect of carvedilol on heart rate corrected QT-interval and QT dispersion in pediatric patients with congestive heart failure. European Heart Journal. 2000; Supplement 21, 436.
35. Mir TS, Eiselt M, Marohn S, Läer S, Behn F, Scholz H, Weil J. Treatment of congestive heart failure with betareceptorblockers on pediatric patients. European Heart Journal. 2000; Supplement 21, 432.
34. Behn F, Läer S, Scholz H, Mir TS, Weil J, Meibohm B. Heart rate and mean arterial pressure during carvedilol therapy in children of different ages. Naunyn Schmiedeberg´s Archives of Pharmacology. 2000; Supplement 361, R 123.
33. Läer S, Behn F, Wauer I, Hulpke-Wette M, Mir TS, Meibohm B. Pharmacokinetics of sotalol in children with supraventricular tachycardia. Clinical Pharmacology & Therapeutics. 2000; 67, PII-63, 130.
1999
32. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Weil J. Differences in carvedilol pharmacokinetics between children and adults. Zeitschrift für Kardiologie. 1999; 88, 758.
31. Mir TS, Eiselt M, Banhidai M, Läer S, Behn F, Scholz H, Weil J. Therapie der chronischen Herzinsuffizienz mit ß-Rezeptorblockern bei pädiatrischen Patienten am Beispiel von Carvedilol. Zeitschrift für Kardiologie. 1999; 88, 758.
30. Ritterbach C, Scholz J, Läer S, Schulte am Esch J. Ein erhöhter Serotoninumsatz unter Allgemeinanaesthesie korreliert mit postoperativer Übelkeit und Erbrechen. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie. 1999; 40, 337.
29. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Venzke A, Weil J, Meibohm B. Carvedilol in children with congestive heart failure. European Journal of Clinical Pharmacology. 1999; 55, A30.
28. Mir TS, Eiselt M, Läer S, Behn F, Venzke A, Scholz H, Weil J. Erweiterte Therapie der Herzinsuffizienz bei pädiatrischen Patienten mit dem ß-Rezeptorenblocker Carvedilol. Zeitschrift für Kardiologie. 1999; 88, 216.
27. Läer S, Behn F, Scholz H, Mir TS, Eiselt M, Venske A, Weil J. Carvedilol therapy in infants - dose adjustment due to genetic polymorphism of cytochrome P450 2D6. Zeitschrift für Kardiologie. 1999; 88, 216.
26. Läer S, Scholz H, Stein B, Uebeler J, Tsilimingas N, Boknik P, Neumann J. Regional expression of 5-HT4 splice variants splice variants in the human heart. Naunyn Schmiedeberg´s Archives of Pharmacology. 1999; Supplement 359, R 105.
25. Arndt J, Läer S, Liebau M, Scholz H, Warnholtz A, Meinertz T. Low dose amiodarone treatment - pharmacodynamic and pharmacokinetic parameters. Naunyn Schmiedeberg´s Archives of Pharmacology. 1999; Supplement 359, R 127.
24. Behn F, Läer S, Scholz H, Mir TS, Eiselt M, Venske A, Weil J, Meibohm B. Carvedilol in children with congestive heart failure - pharmacokinetic parameters. Naunyn Schmiedeberg´s Archives of Pharmacology. 1999; Supplement 359, R 130.
1998
23. Mir TS, Eiselt M, Fenske A, Läer S, Behn F, Scholz H, Weil J. Erste klinische Erfahrungen mit dem ß-Rezeptorenblocker Carvedilol zur Behandlung der Herzinsuffizienz bei Kindern. Zeitschrift für Kardiologie. 1998; 87, 770.
22. Behn F, Läer S, Mir TS, Scholz H, Weil J. Age related sotalol pharmacokinetics require modified dosage regimens in infants. European Journal of Clinical Pharmacology. 1998; 54, A7.
21. Läer S, Neumann J, Remmers F, Scholz H. Comparison of functional coupling and mRNA expression of 5-hydroxytryptamine receptor subtypes in human and rat heart. Naunyn Schmiedeberg´s Archives of Pharmacology. 1998; Supplement 358, R 632.
20. Läer S, Remmers F, Scholz H, Ismail M, Neumann J. Signal transduction of 5-hydroxytryptamine receptors in human and rat atrium. Zeitschrift für Kardiologie. 1998; 87, 279.
19. Remmers F, Läer S, Scholz H, Ismail M, Neumann J. Differences between functional coupling and mRNA expression of 5-hydroxytryptamine receptor subtypes in human and rat atrium. Naunyn Schmiedeberg´s Archives of Pharmacology. 1998; Supplement 357, R 393.
1997
18. Läer S, Scholz H, Ritterbach C, Scholz J. Increased serotonin turnover in patients undergoing surgery with general anaesthesia. Naunyn Schmiedeberg´s Archives of Pharmacology. 1997; Supplement 356, R 53.
17. Läer S, Scholz H, Buschmann I, Thoenes M, Meinertz T. Evidence for a new drug interaction: digitoxin toxicity after amiodarone co-treatment. European Journal of Clinical Pharmacology. 1997; 52, A7.
16. Läer S, Scholz H, Uebeler P, Neumann J. Charakterisierung von Inotropie und Chronotropie am Rattenherzen. Zeitschrift für Kardiologie. 1997; 86, R 1237.
15. Läer S, Apel M, Scholz H, Boknik P, Neumann J. Chronic adrenergic stimulation leads to alterations in serotonin metabolism and cardiac mRNA expression of 5-HT subreceptors in rat. Naunyn Schmiedeberg´s Archives of Pharmacology. 1997; Supplement 355, R 355.
14. Liebau M, Läer S, Scholz H, Neumann J. Interaction between D,L-sotalol and the cholesterol lowering drug colestyramine. Naunyn Schmiedeberg´s Archives of Pharmacology. 1997; Supplement 355, R 450.
1996
13. Läer S, Scholz H, Neumann J, Gams E, Zimmermann N. Amiodarone, sotalol and diltiazem levels in human cardiac tissues. Relations to peroral dosages and blood levels. Acta Physiologica Pharmacologica et Therapeutica Latinoamericana. 1996; 144.
12. Läer S, Scholz H, Neumann J, Gams E, Zimmermann N. Diltiazem levels in human cardiac tissues. Relation to peroral dosage and blood levels. Naunyn Schmiedeberg´s Archives of Pharmacology. 1996; Supplement 353, R 154.
11. Läer S, Scholz H, Neumann J. Tropisetron sensitive 5-hydroxytryptamine subreceptor affects contractility in guinea pig atria. Naunyn Schmiedeberg´s Archives of Pharmacology. 1996; Supplement 353, R 56.
1995
10. Reymann A, Froeschle O, Schäfer A, Bräsen J, Woermann C, Läer S, Meyer Pannwitt W. Pilot study on a clinical assay contributing to diagnosis of multidrug resistance in gastrointestinal tumors. Anticancer Research. 1995; 15 (6A):2437-8.
9. Läer S, Neumann J, Scholz H. Pharmacodynamically relevant interaction between D,L-Sotalol and an antacid preparation (MaaloxR). Circulation. 1995; 8, Supplement I, I-194.
8. Läer S, Neumann J, Scholz H. Interaction between D,L-Sotalol and an antacid preparation (MaaloxR). Thérapie. 1995; 4, Supplement 479.
7. Läer S, Bunge A, Dietel M, Meyer Pannwitt U, Schaefer A, Trapp M, Woermann C, Reymann A. Human leukemia cell lines K562-RADR express low levels of p-glycoproteinmediated multidrug resistence: reference for clinical tumor specimen. Naunyn Schmiedeberg´s Archives of Pharmacology. 1995; Supplement 351, R 20.
1994
6. Läer S, Apel M, Bernhardt J, Kahl R. Bilirubin decreases superoxide anion radical concentration in human neutrophil granulocytes and xanthine oxidase system. Canadian Journal of Physiology and Pharmacology. 1994; Supplement 1, 519.
5. Steinfath M, Scholz J, Reymann A, Läer S, Scholz H, Schulte Am Esch J.Ist das Plasmakonzentrationsprofil von Lidocain abhängig von der endobronchialen Medikamentenapplikation? Der Anaesthesist. 1994; Supplement 78, 24.
4. Läer S, Apel M, Bernhardt J, Kahl R. Bilirubin decreases superoxide anion radical concentration in oxidase systems. Naunyn Schmiedeberg´s Archives of Pharmacology. 1994; Supplement 349, R 119.
1992
3. Läer S, Huether G, Block F, Sontag KH. Stimulation by carbachol of striatal dopamine release is dependent on the degree of prestimulation of opaminergic nerve terminals. European Journal Neuroscience. 1992; Supplement 5, 59.
2. Läer S, Huether G, Block F, Sontag KH. Acute reduction of cerebral blood flow by clamping of both carotid arteries increases dopamin release. Abstracts of the 4th International Symposium on Pharmacology of Cerebral ischemia; 1992; Marburg; 31.
1991
1. Läer S, Block F, Huether G, Reimer A, Sontag KH. Moderate reduction of cerebral blood flow induces changes in extracellular striatal dopamine and its metabolites. in: Synapse, Transmission, Modulation - 19th Gottingen Neurobiology Conference Proceedings; Editions Elsner N; Thieme Verlag, Stuttgart; 1991:375.